Role of CHOP and ER Stress in RGC Degeneration
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
April 01, 2007 - March 31, 2009
Grant ID
G2007062
Acknowledgement
Goals
These experiments seek to determine if inhibition of the stress induced response can reduce or prevent the loss of retinal ganglion cells. If successful, this work could help provide the basis for the development of new strategies for the diagnosis and treatment of glaucoma.
Summary
Glaucoma is a major cause of vision loss. It is the second most common cause of blindness worldwide. In glaucoma, decreased vision is caused by the injury and death of retinal ganglion cells (RGCs), the cells that transmit visual information from the eye to the brain. All current forms of glaucoma treatment (drugs, laser treatment, and surgery) act by lowering the pressure within the eye. Although pressure lowering can be helpful, RGC loss can continue even after pressure reduction. Greater understanding of the molecular mechanisms underlying retinal ganglion cell (RGC) loss will likely make possible the development of more effective diagnostic and treatment strategies. In the work proposed in this application we will explore the molecular mechanisms that actually induce the death of RGCs. In preliminary studies we have shown that a particular pathway, called the stress induced response, is activated in animal models of glaucoma. We propose to study this pathway in more detail, and determine if inhibition of the stress induced response can reduce or prevent the loss of RGCs.
Related Grants
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dan Stamer, PhD
Current Organization
Arizona Board of Regents, University of Arizona
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dan Stamer, PhD
Current Organization
Arizona Board of Regents, University of Arizona
National Glaucoma Research
Enhancing Access to Glaucoma Care Using Artificial Intelligence
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Benjamin Xu, MD, PhD
Current Organization
University of Southern California
Enhancing Access to Glaucoma Care Using Artificial Intelligence
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Benjamin Xu, MD, PhD
Current Organization
University of Southern California